Aeglea BioTherapeutics to Present at BIO Digital 2020

Rhea-AI Summary

Aeglea BioTherapeutics (NASDAQ: AGLE) will present a corporate overview at BIO Digital from June 8-12, 2020. The presentation will be led by President and CEO Anthony G. Quinn, M.B. Ch.B., Ph.D. It can be accessed on-demand by registered participants and will also be available for download on Aeglea's website. Aeglea is focused on developing human enzyme therapeutics for rare diseases, notably its lead candidate pegzilarginase, currently in a Phase 3 trial for Arginase 1 Deficiency. The company has also received regulatory approval for another treatment, ACN00177, for Homocystinuria.

AUSTIN, Texas, June 01, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will provide a corporate overview at BIO Digital being held virtually June 8-12, 2020.

Presentation Details

Date: June 8-12, 2020
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer
Location: https://www.bio.org/events/bio-digital

The presentation will be available for download on the Presentations & Events section of the Company’s website and also will be available on-demand to registered participants of BIO Digital at https://www.bio.org/events/bio-digital/sessions/620997.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. The Company received approval of its Clinical Trial Application (CTA) for ACN00177 for the treatment of Homocystinuria by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA). Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit http://aegleabio.com.

Media Contact:
Kelly Boothe, Ph.D.
Director, Corporate Communications
Aeglea BioTherapeutics
512.399.5458
media@aegleabio.com

Investor Contact:
Joey Perrone
Senior Director, Finance & Investor Relations
Aeglea BioTherapeutics
investors@aegleabio.com

FAQ

What will Aeglea BioTherapeutics present at BIO Digital 2020?

Aeglea will provide a corporate overview led by President and CEO Anthony G. Quinn from June 8-12, 2020.

When is the BIO Digital event where AGLE will present?

The BIO Digital event will take place from June 8-12, 2020.

How can I access Aeglea BioTherapeutics' presentation?

The presentation will be available for download on Aeglea's website and on-demand for registered participants.

What are Aeglea's leading therapeutic candidates?

Aeglea's lead candidate is pegzilarginase, currently in a Phase 3 trial for Arginase 1 Deficiency.

Has Aeglea received any designations for its therapies?

Yes, pegzilarginase has received Rare Pediatric Disease and Breakthrough Therapy Designations.